CompletedPhase 3NCT00105183
EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection
Studying Idiopathic pulmonary fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Neovii Biotech
- Principal Investigator
- Elbert P Trulock III, MDWashington University School of Medicine
- Intervention
- Placebo(biological)
- Enrollment
- 223 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2005 – 2011
Study locations (19)
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- University of California, San Francisco, San Francisco, California, United States
- Stanford University, Stanford, California, United States
- Mayo Clinic, Jacksonville, Florida, United States
- Emory University School of Medicine, Atlanta, Georgia, United States
- University of Iowa Hospital & Clinics, Iowa City, Iowa, United States
- University of Kentucky Medical Center, Lexington, Kentucky, United States
- Barnes-Jewish Hospital, St Louis, Missouri, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- INTEGRIS Baptist Medical Center, Oklahoma City, Oklahoma, United States
- University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
- Temple University Hospital, Philadelphia, Pennsylvania, United States
- Vanderbilt University, Nashville, Tennessee, United States
- Baylor College of Medicine, Houston, Texas, United States
- University of Texas Health Sciences Center, San Antonio, Texas, United States
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00105183 on ClinicalTrials.govOther trials for Idiopathic pulmonary fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05988463Dose-Escalation Study of Artesunate Patients With IPFJoseph C. Wu
- RECRUITINGNANCT07486206Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 TrialHospital de Granollers
- RECRUITINGNANCT07482917Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 TrialHospital de Granollers
- RECRUITINGPHASE2NCT06241560A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodBoehringer Ingelheim
- RECRUITINGPHASE3NCT07201922A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisBoehringer Ingelheim
- RECRUITINGNANCT07466420Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.Katerina M. Antoniou
- RECRUITINGPHASE3NCT07299695Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary FibrosisArgyrios Tzouvelekis
- RECRUITINGPHASE2NCT07284459Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisContineum Therapeutics